The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 615-623

  Ginzburg, Serge ^a   Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Androgen deprivation therapy; Gonadotropin releasing hormone agonist; Gonadotropin releasing hormone antagonist; Orchiectomy; Prostate cancer

Indexed keywords

ABARELIX; BICALUTAMIDE; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DEGARELIX; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANAPHYLAXIS; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANEMIA; ANXIETY DISORDER; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FLUSHING; FOLLOW UP; GYNECOMASTIA; HUMAN; INSULIN RESISTANCE; LIBIDO DISORDER; MALAISE; MASTALGIA; MEMORY DISORDER; METABOLIC SYNDROME X; OBESITY; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; CARCINOMA; DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED PRACTICE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; STANDARD OF CARE; TIME FACTORS;

EID: 80052195839     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.005     Document Type: Review

References (47)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol 2004, 171(4):1393-1401.
3. Huggins C., Hodges C.V. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43:209-223.
4. Byar D.P. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973, 32(5):1126-1130.
5. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967, 124(5):1011-1017.
6. Bailar J.C., Byar D.P. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970, 26(2):257-261.
7. Byar D.P., Corle D.K. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988, (7):165-170.
8. Labrie F., Dupont A., Belanger A., et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983, 4(6):579-594.
9. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321(7):419-424. [Erratum appears in N Engl J Med 1989;321(20):1420].
10. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339(15):1036-1042.
11. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003, 95(13):981-989.
12. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008, 300(2):173-181. [Erratum appears in JAMA 2009;301(1):38].
13. Wong Y.N., Freedland S.J., Egleston B., et al. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009, 56(4):609-616.
14. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002, 167(1):112-116.
15. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002, 90(6):561-566.
16. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004, 292(7):821-827.
17. D'Amico A.V., Loffredo M., Renshaw A.A., et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 2006, 24(25):4190-4195.
18. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373(9660):301-308.
19. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337(5):295-300.
20. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106.
21. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360(24):2516-2527.
22. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341(24):1781-1788.
23. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7(6):472-479.
24. Wong Y.N., Freedland S., Egleston B., et al. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009, 27(1):100-105.
25. Krupski T.L., Smith M.R., Lee W.C., et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004, 101(3):541-549.
26. Wirth M.P., Weissbach L., Marx F.J., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004, 45(3):267-270. [discussion: 270].
27. Wirth M.P., See W.A., McLeod D.G., et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004, 172(5 Pt 1):1865-1870.
28. McLeod D.G., Iversen P., See W.A., et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006, 97(2):247-254.
29. McLeod D.G., See W.A., Klimberg I., et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median follow-up. J Urol 2006, 176(1):75-80.
30. Mohler J., Bahnson R.R., Boston B., et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010, 8(2):162-200.
31. Saylor P.J., Smith M.R. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009, 181(5):1998-2006. [discussion: 2007-8].
32. Schwandt A., Garcia J.A. Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol 2009, 19(3):322-326.
33. Basaria S., Lieb J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56(6):779-786.
34. Hakimian P., Blute M., Kashanian J., et al. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int 2008, 102(11):1509-1514.
35. Tyrrell C.J., Kaisary A.V., Iversen P., et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998, 33(5):447-456.
36. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001, 19(17):3750-3757.
37. Kawakami J., Cowan J.E., Elkin E.P., et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006, 106(8):1708-1714.
38. Scherr D.S., Pitts W.R. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003, 170(5):1703-1708.
39. Cox R.L., Crawford E.D. Estrogens in the treatment of prostate cancer. J Urol 1995, 154(6):1991-1998.
40. Gonzalez-Barcena D., Kastin A.J., Schalch D.S., et al. Synthetic LH-releasing hormone (LH-RH) administered to normal men by different routes. J Clin Endocrinol Metab 1973, 37(3):481-484.
41. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294(2):238-244.
42. Limonta P., Montagnani M., Moretti M., et al. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001, 10:709-720.
43. Klotz L., Boccon-Gibod L., Shore N.D., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008, 102(11):1531-1538.
44. Barradell L.B., Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994, 5(1):59-80.
45. Hellerstedt B. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer. Urology 2003, 62(Suppl 1):79-86.
46. Calais da Silva F.E., Bono A.V., Whelan P., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009, 55(6):1269-1277.
47. Abrahamsson P.A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010, 57(1):49-59.